Your Source of High Quality Pharma Products and Ingredients
Advanced Biomedical Laboratories - Pharmaceuticals is a US based manufacturer of generic pharmaceuticals. Our mission is to play a leading role in the transformation of US and world-wide healthcare.
Advanced Biomedical Laboratories brings raw materials and manufacturers together to create affordable, high-quality, regulatory compliant products through targeting a low cost development pathway.
Our philosophy is simple-responding to customers needs and providing total customer satisfaction. We use customer focused product development and manufacturing coupled with technical innovation, to deliver consistent quality products and create value for our customers.
We manufacture pharmaceuticals and API’s by utilizing an expansive product development methods and knowledge base at our disposal, with in-house technical and regulatory expertise. These pharmaceuticals are manufactured by Advanced Biomedical Laboratories through collaborations with our partners. We have entered into strategic collaboration with US-based and worldwide manufacturers to develop and market pharmaceuticals. We also manufacture and market branded prescription drugs under exclusive licensing agreements.
Our range of products under development include:
Primarily through our pharmaceuticals business, Advanced Biomedical laboratories develops, manufactures and markets the complex chemicals, intermediates and active pharmaceutical ingredients (API’s) used worldwide by the generic drug industry. Some of these ingredients are used in-house in Advanced Biomedical Laboratories own finished pharmaceutical products. We manufacture API’s at our collaborators facilities in New Zealand, United states and worldwide. Our exclusive alliance with our product development and manufacturing partners seamlessly transitions our bench-scale synthetic chemistry process development and optimization and natural product isolations to multi-kilogram and cGMP manufacture.
As a reliable Scientific resource for you, here we have assembled a set of links to technical documents designed to provide information on drugs, providers of disease-specific information, drug discovery and development information and health advocacy groups and policy, and industry forums and professional meetings.
Cancer Drug Shortages Greatly Affect Patients with Blood Cancer, Families Across the US
May 23, 2023
Patients with blood cancer want their disease to be treated with the best available therapies and feel confident that they’ll be available when they go to receive treatment.
Read More
Researchers discover key mutation in acute myeloid leukemia
November 10, 2010
NIH-supported discovery may lead to treatment changes; demonstrates power of The Cancer Genome Atlas strategy. Researchers have discovered mutations in a particular gene that affects the treatment prognosis for some patients with acute myeloid leukemia (AML), an aggressive blood cancer that kills 9,000 Americans annually. The scientists report their results in the Nov. 11, 2010, online issue of The New England Journal of Medicine.
Read More
FDA Approves New Treatment for Rare Blood Disorder
June 6, 2023
Rye Brook, N.Y., June 6, 2023 The U.S. Food and Drug Administration (FDA) recently approved avapritinib (Ayvakit®) to treat adults with indolent systemic mastocytosis. Systemic mastocytosis occurs when the body produces irregular mast cells, which are a type of white blood cell. Symptoms of indolent (slow growing) systemic mastocytosis often go unnoticed for years and may develop in an individual’s skin, liver, spleen, or gastrointestinal tract. Although it begins as a slow growing condition, indolent systemic mastocytosis can become cancerous in up to 3 in 10 adults who have it.
Read More
FDA Approves New Bispecific Antibody for Non-Hodgkin Lymphoma Subtype
June 6, 2023
Rye Brook, N.Y., May 31, 2023 – The U.S. Food and Drug Administration (FDA) on May 19, 2023, approved epcoritamab (Epkinly™) to treat adults with diffuse large B-cell lymphoma (DLBCL), whose disease has not responded or relapsed after two prior therapies.
Read More
International scientific, medical, & family conference
July 29 – August 3, 2024
The Hyatt Regency Coconut Point Resort and Spa in Bonita Springs, Florida. The Barth Syndrome Foundation's (BSF) biennial conferences bring affected families, research scientists, and clinicians together in one place at one time for a dual track meeting. BSF and our affiliates in Canada, France, Italy, and the United Kingdom firmly believe that while each of these groups can make some progress in their individual efforts, together, we are so much more powerful.
Read More